What is amylin and why target it for weight loss?

Amylin is a 37-amino acid peptide hormone secreted alongside insulin from pancreatic beta cells after meals. Its job is to help regulate glucose and appetite: it slows gastric emptying (so glucose enters blood more gradually), suppresses glucagon (which raises blood sugar), and signals satiety to the brain via the area postrema. People with diabetes often have disrupted amylin signaling. Pramlintide (Symlin) was the first amylin analog approved for diabetes, but required multiple daily injections and caused modest weight loss. Cagrilintide improves on pramlintide with once-weekly dosing and stronger weight loss effects. The key insight: amylin and GLP-1 work through different brain pathways for satiety, so combining them produces additive effects rather than redundancy.

What is CagriSema and why is it so promising?

CagriSema is the combination of cagrilintide plus semaglutide in a single injection—Novo Nordisk's bid for best-in-class obesity treatment. Phase 2 results showed approximately 24% weight loss at 68 weeks, exceeding either drug alone. The logic is biological: GLP-1 and amylin activate different receptor systems and brain regions involved in appetite. Combining them hits satiety from multiple angles. It's like the combination drug approach that works in HIV and hypertension—multiple mechanisms outperform single targets. If phase 3 trials confirm these results, CagriSema could become the most effective obesity medication available. Novo Nordisk is investing heavily in manufacturing capacity, anticipating massive demand.

How does cagrilintide compare to pramlintide (Symlin)?

Same target, vastly different practicality. Pramlintide is a first-generation amylin analog requiring injections before each meal (2-3x daily) due to short half-life. It's approved for diabetes, not obesity, and produces modest weight loss (a few pounds). Cagrilintide is acylated (fatty acid attached) to extend half-life to about a week, enabling once-weekly injection. Its weight loss effect is substantially greater—around 10% as monotherapy versus pramlintide's 2-3%. Cagrilintide is in development specifically for obesity, while pramlintide remains a niche diabetes treatment most physicians find too cumbersome to prescribe. Cagrilintide essentially makes amylin therapy practical for the first time.

What does cagrilintide do differently than semaglutide?

Different receptors, different pathways, synergistic effects. Semaglutide activates GLP-1 receptors in the hypothalamus and brainstem to suppress appetite, in the gut to slow emptying, and in the pancreas to enhance insulin. Cagrilintide activates amylin/calcitonin receptors (AMY receptors) in the area postrema—a brainstem region involved in satiety and nausea—and shares some effects on gastric emptying. The brain regions involved partially overlap but aren't identical, which is why combining them enhances appetite suppression beyond either alone. Cagrilintide also suppresses glucagon more directly than GLP-1. Think of them as two different phone lines both calling the brain to say 'stop eating.'

What are the side effects of cagrilintide?

Similar to other satiety-affecting drugs: nausea, vomiting, diarrhea, and decreased appetite are most common, especially during dose escalation. These typically improve over time. Because cagrilintide affects the area postrema (the brain's nausea center), GI effects are somewhat expected. Injection site reactions occur occasionally. In combination with semaglutide, the side effect burden is at least additive—combining two drugs with GI effects means more GI effects, at least initially. The slow titration protocols help. Hypoglycemia risk exists when combined with insulin or sulfonylureas. Long-term safety data from phase 3 trials will be important for characterizing risks.

When will cagrilintide/CagriSema be available?

Phase 3 trials (REDEFINE program) are ongoing with results expected in 2024-2025. If successful, FDA approval could come in 2025-2026. However, Novo Nordisk is already struggling to meet demand for Wegovy (semaglutide); adding CagriSema to production will require significant manufacturing expansion. Availability may be limited initially, similar to Wegovy's chronic shortage situation. The company is investing billions in new production facilities, but pharmaceutical manufacturing scale-up takes years. Expect initial availability to be constrained even after approval. Whether CagriSema is positioned as a premium next-generation option or a replacement for Wegovy will affect access patterns.

Will insurance cover cagrilintide or CagriSema?

Uncertain, but likely to follow existing GLP-1 patterns. Most private insurance currently excludes weight loss medications, though this is slowly changing as obesity is increasingly recognized as a disease. Medicare is prohibited by law from covering obesity drugs (though legislation is pending to change this). If CagriSema is also approved for diabetes, coverage through diabetes benefits might be possible like Ozempic. The cost will almost certainly be premium—likely similar to or higher than Wegovy ($1,000+/month without insurance). Employer-sponsored plans are increasingly adding obesity drug coverage due to downstream health cost savings. The coverage landscape is evolving but remains a major access barrier.

Homechevron_rightPeptideschevron_rightCagrilintide

Metabolic

scheduleHalf-life: ~7 days (enabling once-weekly dosing)

Cagrilintide

Cagrilintide (NN9838, AM833)

Cagrilintide takes obesity treatment in a different direction by targeting amylin, a hormone co-secreted with insulin from pancreatic beta cells. Amylin naturally promotes satiety, slows gastric emptying, and suppresses glucagon—effects that complement GLP-1 but through distinct pathways. The problem with native amylin is it's short-lived and tends to aggregate. Cagrilintide is an acylated analog designed for once-weekly dosing with improved stability. Alone, it produces meaningful weight loss, but the real excitement is the combination with semaglutide (called CagriSema). Phase 2 trials showed this combination produces weight loss approaching 25%—potentially the most effective obesity treatment ever tested. By hitting both amylin and GLP-1 pathways, you get additive appetite suppression through different brain circuits. Novo Nordisk is racing this through development as the potential successor to Wegovy. Cagrilintide represents the emerging understanding that obesity is a multi-pathway disease requiring multi-pathway treatment.

What is Cagrilintide?
Research Benefits
How Cagrilintide Works
Research Applications

References

What is Cagrilintide?

Research Benefits

check_circle

Significant appetite suppression

check_circle

Enhanced satiety after meals

check_circle

Slows gastric emptying

check_circle

Suppresses glucagon secretion

check_circle

Once-weekly dosing convenience

check_circle

Synergistic with GLP-1 agonists

check_circle

May improve glycemic control

check_circle

Potential for best-in-class weight loss when combined

Research Applications

science

Obesity treatment (monotherapy and combination)

Active research area with published studies

science

Type 2 diabetes

Active research area with published studies

science

CagriSema combination therapy

Active research area with published studies

science

Metabolic syndrome

Active research area with published studies

science

Weight maintenance after loss

Active research area with published studies

science

Food intake regulation

Active research area with published studies

science

Satiety signaling

Active research area with published studies

science

Glucagon suppression

Active research area with published studies

Frequently Asked Questions

Scientific References

Cagrilintide Plus Semaglutide for Obesity: Phase 2 Results

The Lancet (2023)

open_in_new

Amylin Analogs in the Treatment of Obesity

Obesity Reviews (2022)

open_in_new

Dual Amylin and GLP-1 Receptor Agonism for Weight Management

Diabetes Care (2024)

open_in_new

Cagrilintide (NN9838, AM833)

What is Cagrilintide?

Research Benefits

check_circle

Significant appetite suppression

check_circle

Enhanced satiety after meals

check_circle

Slows gastric emptying

check_circle

Suppresses glucagon secretion

check_circle

Once-weekly dosing convenience

check_circle

Synergistic with GLP-1 agonists

check_circle

May improve glycemic control

check_circle

Potential for best-in-class weight loss when combined

Research Applications

science

Obesity treatment (monotherapy and combination)

Active research area with published studies

science

Type 2 diabetes

Active research area with published studies

science

CagriSema combination therapy

Active research area with published studies

science

Metabolic syndrome

Active research area with published studies

science

Weight maintenance after loss

Active research area with published studies

science

Food intake regulation

Active research area with published studies

science

Satiety signaling

Active research area with published studies

science

Glucagon suppression

Active research area with published studies

Frequently Asked Questions

Cagrilintide

Cagrilintide (NN9838, AM833)

Table of Contents

What is Cagrilintide?

Research Benefits

Research Applications

Obesity treatment (monotherapy and combination)

Type 2 diabetes

CagriSema combination therapy

Metabolic syndrome

Weight maintenance after loss

Food intake regulation

Satiety signaling

Glucagon suppression

Frequently Asked Questions

What is amylin and why target it for weight loss?

What is CagriSema and why is it so promising?

How does cagrilintide compare to pramlintide (Symlin)?

What does cagrilintide do differently than semaglutide?

What are the side effects of cagrilintide?

When will cagrilintide/CagriSema be available?

Will insurance cover cagrilintide or CagriSema?

Scientific References

Cagrilintide Plus Semaglutide for Obesity: Phase 2 Results

Amylin Analogs in the Treatment of Obesity

Dual Amylin and GLP-1 Receptor Agonism for Weight Management

Quick Reference

Related Peptides

Cagrilintide

Cagrilintide (NN9838, AM833)

Table of Contents

What is Cagrilintide?

Research Benefits

Research Applications

Obesity treatment (monotherapy and combination)

Type 2 diabetes

CagriSema combination therapy

Metabolic syndrome

Weight maintenance after loss

Food intake regulation

Satiety signaling

Glucagon suppression

Frequently Asked Questions

What is amylin and why target it for weight loss?

What is CagriSema and why is it so promising?

How does cagrilintide compare to pramlintide (Symlin)?

What does cagrilintide do differently than semaglutide?

What are the side effects of cagrilintide?

When will cagrilintide/CagriSema be available?

Will insurance cover cagrilintide or CagriSema?

Scientific References

Cagrilintide Plus Semaglutide for Obesity: Phase 2 Results

Amylin Analogs in the Treatment of Obesity

Dual Amylin and GLP-1 Receptor Agonism for Weight Management

Quick Reference

Related Peptides